Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV and Oral Migalastat in Healthy Volunteers
NCT02082327Phase 1Completed
- Sponsor
- Amicus Therapeutics
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of migalastat in Fabry disease (FD) (5 arms), sponsored by Amicus Therapeutics. Primary endpoints: Plasma pharmacokinetics of migalastat at 48 hours and Safety and tolerability of migalastat at 48 hours. Started Mar 2014; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT02082327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082327.